DK3544976T3 - N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamid-fri base hæmihydrat, fremgangsmåder til fremstilling og anvendelser deraf - Google Patents

N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamid-fri base hæmihydrat, fremgangsmåder til fremstilling og anvendelser deraf Download PDF

Info

Publication number: DK3544976T3
Authority: DK; Denmark
Prior art keywords: methyl; hemy; aminosulphonyl; thiazol; pyridinyl
Prior art date: 2016-11-28

Application number

DK17811883.2T

Other languages

English (en)

Inventor

Yogeshwar Bachhav

Wilfried Schwab

Alexander Birkmann

Kurt Voegtli

Original Assignee

Aicuris Gmbh & Co Kg

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-11-28

Filing date

2017-11-28

Publication date

2021-05-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57421711&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3544976(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2017-11-28 Application filed by Aicuris Gmbh & Co Kg filed Critical Aicuris Gmbh & Co Kg

2021-05-10 Application granted granted Critical

2021-05-10 Publication of DK3544976T3 publication Critical patent/DK3544976T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Virology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Ophthalmology & Optometry (AREA)
Bioinformatics & Cheminformatics (AREA)
Oil, Petroleum & Natural Gas (AREA)
Inorganic Chemistry (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicinal Preparation (AREA)

DK17811883.2T 2016-11-28 2017-11-28 N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamid-fri base hæmihydrat, fremgangsmåder til fremstilling og anvendelser deraf DK3544976T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP16200967		2016-11-28
PCT/EP2017/080653 WO2018096170A1 (en)	2016-11-28	2017-11-28	N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide free base hemihydrate, methods of manufacture and uses thereof

Publications (1)

Publication Number	Publication Date
DK3544976T3 true DK3544976T3 (da)	2021-05-10

Family

ID=57421711

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK21157420.7T DK3848369T3 (da)	2016-11-28	2017-11-28	N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamid-fri base hæmihydrat, fremgangsmåder til fremstilling og anvendelser deraf
DK17811883.2T DK3544976T3 (da)	2016-11-28	2017-11-28	N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamid-fri base hæmihydrat, fremgangsmåder til fremstilling og anvendelser deraf

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK21157420.7T DK3848369T3 (da)	2016-11-28	2017-11-28	N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamid-fri base hæmihydrat, fremgangsmåder til fremstilling og anvendelser deraf

Country Status (22)

Country	Link
US (3)	US11021474B2 (da)
EP (3)	EP3544976B1 (da)
JP (2)	JP6978501B2 (da)
KR (2)	KR102536156B1 (da)
CN (1)	CN109996798B (da)
AR (1)	AR110249A1 (da)
AU (3)	AU2017365632B2 (da)
CA (1)	CA3045059A1 (da)
CY (1)	CY1124523T1 (da)
DK (2)	DK3848369T3 (da)
ES (2)	ES2941390T3 (da)
HR (1)	HRP20210720T1 (da)
HU (1)	HUE054703T2 (da)
LT (1)	LT3544976T (da)
PL (1)	PL3544976T3 (da)
PT (2)	PT3848369T (da)
RS (1)	RS61905B1 (da)
SI (2)	SI3544976T1 (da)
SM (1)	SMT202100279T1 (da)
TW (2)	TWI811800B (da)
UY (1)	UY37496A (da)
WO (1)	WO2018096170A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2573085A1 (en)	2011-09-26	2013-03-27	AiCuris GmbH & Co. KG	N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range
PT3848369T (pt) *	2016-11-28	2023-04-10	Aicuris Gmbh & Co Kg	Hemi-hidrato da base livre de n-[5-(aminossulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, métodos de fabricação e suas utilizações
WO2018096177A1 (en) *	2016-11-28	2018-05-31	Aicuris Anti-Infective Cures Gmbh	A maleate salt of the free base of n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide, pharmaceutical formulations, methods of manufacture and uses thereof for the treatment of herpes viruses
AR113344A1 (es)	2017-10-05	2020-04-22	Innovative Molecules Gmbh	Enantiómeros de una serie de compuestos antivirales
TW202038947A (zh)	2018-11-28	2020-11-01	德商創新分子有限責任公司	在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
EP3925595A1 (en) *	2020-06-17	2021-12-22	AiCuris GmbH & Co. KG	Ophthalmic formulation comprising n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl] acetamide hemihydrate
EP4096632A1 (en) *	2020-03-26	2022-12-07	AiCuris GmbH & Co. KG	Ophthalmic formulation comprising n-[5-(aminosulfonyl)-4-methyl-1,3- thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide hemihydrate
CN119731171A (zh)	2022-08-29	2025-03-28	组装生物科学股份有限公司	普瑞利韦的新的结晶形式
EP4581030A1 (en)	2022-08-29	2025-07-09	Assembly Biosciences, Inc.	A novel crystalline form of pritelivir

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5496820A (en) *	1988-10-20	1996-03-05	Peraelampi; Markku	Ophthalmic use of S-timolol hemihydrate
DOP2000000109A (es) *	1999-12-23	2002-08-30	Gerald Kleymann	Derivados de tiazolilamida
DE10129714A1 (de)	2001-06-22	2003-01-02	Bayer Ag	Topische Anwendung von Thiazolylamiden
DE102005014248A1 (de) *	2005-03-30	2006-10-05	Aicuris Gmbh & Co. Kg	Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid
EP2573086A1 (en) *	2011-09-26	2013-03-27	AiCuris GmbH & Co. KG	N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
EP2573085A1 (en)	2011-09-26	2013-03-27	AiCuris GmbH & Co. KG	N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range
PT3848369T (pt)	2016-11-28	2023-04-10	Aicuris Gmbh & Co Kg	Hemi-hidrato da base livre de n-[5-(aminossulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, métodos de fabricação e suas utilizações
WO2018096177A1 (en) *	2016-11-28	2018-05-31	Aicuris Anti-Infective Cures Gmbh	A maleate salt of the free base of n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide, pharmaceutical formulations, methods of manufacture and uses thereof for the treatment of herpes viruses
EP4096632A1 (en) *	2020-03-26	2022-12-07	AiCuris GmbH & Co. KG	Ophthalmic formulation comprising n-[5-(aminosulfonyl)-4-methyl-1,3- thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide hemihydrate

2017
- 2017-11-28 PT PT211574207T patent/PT3848369T/pt unknown
- 2017-11-28 ES ES21157420T patent/ES2941390T3/es active Active
- 2017-11-28 CN CN201780073223.2A patent/CN109996798B/zh active Active
- 2017-11-28 SM SM20210279T patent/SMT202100279T1/it unknown
- 2017-11-28 HU HUE17811883A patent/HUE054703T2/hu unknown
- 2017-11-28 JP JP2019528091A patent/JP6978501B2/ja active Active
- 2017-11-28 SI SI201730749T patent/SI3544976T1/sl unknown
- 2017-11-28 RS RS20210576A patent/RS61905B1/sr unknown
- 2017-11-28 WO PCT/EP2017/080653 patent/WO2018096170A1/en not_active Ceased
- 2017-11-28 TW TW110135747A patent/TWI811800B/zh active
- 2017-11-28 LT LTEP17811883.2T patent/LT3544976T/lt unknown
- 2017-11-28 DK DK21157420.7T patent/DK3848369T3/da active
- 2017-11-28 HR HRP20210720TT patent/HRP20210720T1/hr unknown
- 2017-11-28 EP EP17811883.2A patent/EP3544976B1/en active Active
- 2017-11-28 SI SI201731326T patent/SI3848369T1/sl unknown
- 2017-11-28 KR KR1020197018286A patent/KR102536156B1/ko active Active
- 2017-11-28 EP EP21157420.7A patent/EP3848369B1/en active Active
- 2017-11-28 EP EP22211343.3A patent/EP4201934A1/en not_active Withdrawn
- 2017-11-28 KR KR1020237017062A patent/KR102622289B1/ko active Active
- 2017-11-28 PL PL17811883T patent/PL3544976T3/pl unknown
- 2017-11-28 US US16/464,448 patent/US11021474B2/en active Active
- 2017-11-28 CA CA3045059A patent/CA3045059A1/en active Pending
- 2017-11-28 PT PT178118832T patent/PT3544976T/pt unknown
- 2017-11-28 AR ARP170103302A patent/AR110249A1/es not_active Application Discontinuation
- 2017-11-28 DK DK17811883.2T patent/DK3544976T3/da active
- 2017-11-28 UY UY0001037496A patent/UY37496A/es active IP Right Grant
- 2017-11-28 TW TW106141448A patent/TWI737861B/zh active
- 2017-11-28 ES ES17811883T patent/ES2870614T3/es active Active
- 2017-11-28 AU AU2017365632A patent/AU2017365632B2/en active Active
2021
- 2021-04-02 US US17/221,000 patent/US12152022B2/en active Active
- 2021-05-13 CY CY20211100407T patent/CY1124523T1/el unknown
- 2021-08-27 AU AU2021221901A patent/AU2021221901B2/en active Active
- 2021-11-11 JP JP2021184218A patent/JP7289891B2/ja active Active
2022
- 2022-11-03 AU AU2022263540A patent/AU2022263540A1/en not_active Abandoned
2024
- 2024-10-17 US US18/918,528 patent/US20250042893A1/en active Pending

Also Published As

Publication number	Publication date
JP2022024043A (ja)	2022-02-08
JP2020509991A (ja)	2020-04-02
TW202207924A (zh)	2022-03-01
TWI737861B (zh)	2021-09-01
HUE054703T2 (hu)	2021-09-28
SI3544976T1 (sl)	2021-08-31
PL3544976T3 (pl)	2021-11-02
AR110249A1 (es)	2019-03-13
TWI811800B (zh)	2023-08-11
CN109996798B (zh)	2023-05-05
UY37496A (es)	2018-06-29
ES2870614T3 (es)	2021-10-27
DK3848369T3 (da)	2023-03-27
US20210269429A1 (en)	2021-09-02
CY1124523T1 (el)	2022-07-22
AU2021221901A1 (en)	2021-09-23
AU2017365632A1 (en)	2019-06-13
PT3848369T (pt)	2023-04-10
CN109996798A (zh)	2019-07-09
CA3045059A1 (en)	2018-05-31
EP3544976B1 (en)	2021-02-17
EP3848369B1 (en)	2023-01-11
JP6978501B2 (ja)	2021-12-08
US12152022B2 (en)	2024-11-26
AU2021221901B2 (en)	2022-08-11
KR20230075524A (ko)	2023-05-31
EP3848369A1 (en)	2021-07-14
EP3544976A1 (en)	2019-10-02
LT3544976T (lt)	2021-08-10
JP7289891B2 (ja)	2023-06-12
KR102622289B1 (ko)	2024-01-05
KR20190085115A (ko)	2019-07-17
HRP20210720T1 (hr)	2021-09-03
SI3848369T1 (sl)	2023-07-31
CN116804007A (zh)	2023-09-26
TW201825483A (zh)	2018-07-16
US20250042893A1 (en)	2025-02-06
AU2022263540A1 (en)	2022-12-08
WO2018096170A9 (en)	2019-12-19
AU2017365632B2 (en)	2021-07-15
EP4201934A1 (en)	2023-06-28
US20200123145A1 (en)	2020-04-23
ES2941390T3 (es)	2023-05-22
RS61905B1 (sr)	2021-06-30
PT3544976T (pt)	2021-05-18
WO2018096170A1 (en)	2018-05-31
US11021474B2 (en)	2021-06-01
KR102536156B1 (ko)	2023-05-25
SMT202100279T1 (it)	2021-07-12

Publication	Publication Date	Title
DK3544976T3 (da)	2021-05-10	N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamid-fri base hæmihydrat, fremgangsmåder til fremstilling og anvendelser deraf
DK3775092T3 (da)	2023-02-27	Stabiliserede fluoroolefinsammensætninger og fremgangsmåder til fremstilling, oplagring og anvendelse deraf
DK3385262T3 (da)	2022-10-10	4-(3h-indol-5-yl)-n-(pyridin-2-yl)pyrimidin-2-aminderivater som proteinkinaseinhibitorer, fremstillingsfremgangsmåde og medicinsk anvendelse deraf
EP3504590A4 (en)	2020-07-29	MULTISPECTRAL ASSESSMENT OF MOBILE FABRIC
DK2602258T3 (da)	2014-04-22	N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid-mesylat-monohydrat
GB201609607D0 (en)	2016-07-13	Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
DK3436022T3 (da)	2022-06-20	Oxysteroler og fremgangsmåder til anvendelse heraf
DK3154950T3 (da)	2020-09-14	N-(cyanmethyl)-4-(2-(4-morpholinphenylamino)pyrimidin-4-yl)benzamidhydrochloridsalte
DK3873600T5 (da)	2024-03-18	Pyridinylsulfonamidderivater, farmaceutiske sammensætninger og anvendelser deraf
DK3535397T3 (da)	2022-01-31	Alfa-v-beta-6-integrin-ligander og anvendelser deraf
HUE063043T2 (hu)	2023-12-28	Eljárás N-(5-(4-(4-formil-3-fenil-1H-pirazol-1-il)-pirimidin-2-il-amino)-4-metoxi-2-morfolinofenil)-akrilamid elõállítására
DK3612579T3 (da)	2022-02-14	Pultrudat, fremstilling og anvendelse heraf
EP3907159C0 (de)	2024-10-30	Einportionenpackung und verwendung
DK3255046T3 (da)	2020-01-20	Hydroxyethylsulfonat af cyclin-afhængig proteinkinasehæmmer, krystallinsk form deraf og fremgangsmåde til fremstilling deraf
DK3256479T3 (da)	2020-11-02	4-substituerede benzoxaborolforbindelser og anvendelser deraf
DK3343077T3 (da)	2019-09-23	Modtryksklapventilarrangement og anvendelse deraf.
NO2025010I1 (no)	2025-02-14	Combination of epinephrine or a salt thereof, and dodecylmaltoside
PL3544977T3 (pl)	2021-11-08	Sól maleinianowa wolnej zasady n-[5-(aminosulfonylo)-4-metylo-1,3-tiazol-2-ilo]-n-metylo-2-[4-(2-pirydynylo)fe¬nylo]acetamidu, preparaty farmaceutyczne, sposoby wytwarzania oraz ich zastosowania do leczenia wirusa opryszczki
EP3314653A4 (en)	2019-05-01	STACKABLE THIN FILM MEMORY
EP3643708C0 (en)	2025-09-24	2-[4-(METHYLAMINOMETHYL)PHENYL]-5-FLUORO-BENZOFURAN-7-CARBOXAMIDE HYDROCHLORIDE POLYMORPH, ITS PREPARATION PROCESS AND APPLICATION
IL265893A (en)	2019-06-30	Crystal forms of 4-(2-((r1(2r,-2-hydroxycyclohexylamino)benzothiazol-6-yloxy)-n-methylpicolinamide
DK3424911T3 (da)	2021-10-11	Posaconazol, sammensætning, intermediat, fremstillingsfremgangsmåde derfor og anvendelser deraf
SG11201605866YA (en)	2016-08-30	Pharmaceutical composition including 5-{4-(aminosulfonyl)phenyl}-2,2-dimethyl-4-(3-fluorophenyl)-3(2h)-furanone and capsule formulation including the pharmaceutical composition
MA43157A (fr)	2018-09-12	Sels de 1-(4-(2-((1-(3,4-difluorophényl)-1h-pyrazol-3-yl)méthoxy)éthyl) pipérazin-1-yl)éthanone
TH1501007768A (th)	2018-03-08	N-(4-ไฮดรอกซี-4-เมทธิล-ไซโคลเฮกซิล)-4-ฟีนิล-เบนซีนซัลโฟนาไมด์ และ n- (4-ไฮดรอกซี-4-เมทธิล-ไซโคลเฮกซิล)-4-(2-ไพริดิล)เบนซีนซัลโฟนาไมด์ และ การใช้ทางการรักษาโรคของพวกมัน